Cadrenal Therapeutics, Inc. (CVKD)
| Market Cap | 15.56M -38.2% |
| Revenue (ttm) | n/a |
| Net Income | -11.89M |
| EPS | -5.57 |
| Shares Out | 3.08M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 47,562 |
| Open | 5.25 |
| Previous Close | 5.27 |
| Day's Range | 5.04 - 5.60 |
| 52-Week Range | 4.21 - 16.25 |
| Beta | 1.83 |
| Analysts | Strong Buy |
| Price Target | 13.00 (+157.17%) |
| Earnings Date | May 7, 2026 |
About CVKD
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatm... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for CVKD stock is "Strong Buy" and the 12-month stock price target is $13.0.
News
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
PONTE VEDRA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombo...
Cadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA
Cadrenal Therapeutics (CVKD) announced a regulatory milestone after completing its End-of-Phase 2 meeting with the FDA and receiving guidance on key elements of the Phase 3 pivotal trial for CAD-1005,...
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to stand...
Cadrenal Therapeutics files to sell 1.18M shares of common stock for holders
06:04 EDT Cadrenal Therapeutics (CVKD) files to sell 1.18M shares of common stock for holders
Cadrenal Therapeutics price target lowered to $13 from $32 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Cadrenal Therapeutics (CVKD) to $13 from $32 and keeps a Buy rating on the shares to account for updated share count and…
Cadrenal Therapeutics Inc trading halted, volatility trading pause
15:29 EDT Cadrenal Therapeutics (CVKD) Inc trading halted, volatility trading pause
Cadrenal Therapeutics Inc trading resumes
15:34 EDT Cadrenal Therapeutics (CVKD) Inc trading resumes
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Cadrenal's near-term development priority; broader 12-LOX platform remains a longer-term opportunity E...
Cadrenal Therapeutics Transcript: Life Sciences Virtual Investor Forum
CAD-1005, a novel IV therapy for HIT, is advancing to phase III after promising phase II results and strong safety data. The drug targets a major unmet need, holds Orphan Drug and Fast Track status, and may have broader applications in diabetes and obesity.
Cadrenal Therapeutics highlights research on 12-LOX inhibition
Cadrenal Therapeutics (CVKD) highlighted recent scientific findings demonstrating the potential of its first-in-class 12-lipoxygenase, 12-LOX, inhibitor, CAD-1005, to target inflammatory consequences ...
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
PONTE VEDRA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thromboti...
Cadrenal Therapeutics highlights recent 12-LOX inhibitor platform expansion
Cadrenal Therapeutics (CVKD) provided additional perspectives on development opportunities following its recent pipeline expansion with the addition of 12-LOX inhibitors. As previously announced, Cadr...
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition beyond HIT PONTE VEDRA, Fla., Mar...
Cadrenal Therapeutics announces Phase 2 results for CAD-1005
Cadrenal Therapeutics (CVKD) announced results from a Phase 2 trial evaluating CAD-1005 in patients with heparin-induced thrombocytopenia, a severe pro-thrombotic reaction to heparin, the most commonl...
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase 2...
Cadrenal Therapeutics Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit
The discussion highlighted a portfolio targeting critical gaps in anticoagulation, with VLX-1005 and Tecarfarin advancing for rare, high-risk patients. VLX-1005's novel 12-LOX inhibition approach in HIT, regulatory advantages, and upcoming milestones position it as a key near-term value driver.
Cadrenal Therapeutics highlights VLX-1005 as potential therapeutic solution
Cadrenal Therapeutics (CVKD) highlighted the significant unmet medical need in heparin-induced thrombocytopenia and underscored the promise of its recently acquired investigational drug candidate, VLX...
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor
SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current a...
Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System
PONTE VEDRA, FL / ACCESS Newswire / December 30, 2025 / Some companies enter a market because they see opportunity. Others step in because the situation has become unsustainable, and someone has to fi...
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On
PONTE VEDRA, FL / ACCESS Newswire / December 29, 2025 / Every industry has its forgotten corners. In anticoagulation, those corners turned into entire neighborhoods.
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026
PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of curre...
Cadrenal's Quiet Expansion Play Is Starting to Get Loud
PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ: CVKD) entered the back half of the year with a calm, almost surgical approach to building out its foundation. Wh...
Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market
PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) believes it continues to be misread by the market. Yes, the Company is intentionally narrowly focused.
Cadrenal Therapeutics acquires VLX-1005 for heparin-induced thrombocytopenia
Cadrenal Therapeutics (CVKD) acquired VLX-1005 and related 12-lipoxygenase assets from Veralox Therapeutics. The acquisition adds a late-stage, first-in-class drug candidate targeting a critical immun...
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of curre...